Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 2:52 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 721–744 of 1,574 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Period B Clear all

Conditions: Relapsed/Refractory Multiple Myeloma
Interventions: KITE-585, Cyclophosphamide, Fludarabine; Genetic · Drug
Lead sponsor: Kite, A Gilead Company; Industry
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 9
States / cities: Los Angeles, California • Tampa, Florida • Atlanta, Georgia + 6 more

Conditions: Food Effect in Healthy Participants
Interventions: CRS3123 200 mg capsule; Drug
Lead sponsor: Crestone, Inc; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Herpes Zoster, Pneumococcal Infections
Interventions: Enhanced immunization delivery model, Immunization update; Behavioral · Other
Lead sponsor: Auburn University; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 2
States / cities: Auburn, Alabama • Claremont, California

Conditions: Cystic Fibrosis
Interventions: AquADEKs-2, control multivitamin; Drug · Dietary Supplement
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 10 Years and older
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 15
States / cities: Tucson, Arizona • Aurora, Colorado • Orlando, Florida + 12 more

Conditions: Healthy Volunteers
Interventions: Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) - Reference, Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) - Test; Drug
Lead sponsor: Spero Therapeutics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Pemphigus
Interventions: Ofatumumab, Acetaminophen/paracetamol, Antihistamine (cetirizine or equivalent), Prednisone/Prednisolone; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: Not listed
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 2
States / cities: Los Angeles, California • Ann Arbor, Michigan

Conditions: Healthy
Interventions: JNJ-42847922, Midazolam, Warfarin; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Advanced Solid Tumor
Interventions: Gotistobart; Drug
Lead sponsor: OncoC4, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2037
U.S. locations: 2
States / cities: Fort Worth, Texas • Tyler, Texas

Conditions: Healthy Volunteers
Interventions: TAK-994, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 40 Years · Male only
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Type 2 Diabetes Mellitus
Interventions: 2.5 mg Saxagliptin tablet, 5 mg dapagliflozin / 1000 mg metformin XR tablet, Triple FCDP - 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR, 5 mg saxagliptin, 10 mg dapagliflozin / 1000 mg metformin XR tablet, Triple FCDP - 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 85 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Vaginal Microbiota
Interventions: Tampon A, Tampon B; Device
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older · Female only
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Dementia, Mild Cognitive Impairment, Alzheimer Disease
Interventions: In-Home Technology System, Limited In-Home Technology; Device
Lead sponsor: University of California, Berkeley; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Berkeley, California

Conditions: Diabetes Mellitus, Type 2
Interventions: LY2409021, Placebo, Moxifloxacin; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 67 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Ocular Hypertension, Open-Angle Glaucoma
Interventions: Latanoprost Punctal Plug Delivery System (L-PPDS); Drug
Lead sponsor: Mati Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 18
States / cities: Chandler, Arizona • Phoenix, Arizona • Torrance, California + 15 more

Conditions: Renal Cell Carcinoma
Interventions: Sorafenib, temsirolimus (Torisel); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 512 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 26
States / cities: Duarte, California • La Jolla, California • Los Angeles, California + 19 more

Conditions: Healthy
Interventions: PF-07258669, Itraconazole; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: Hollywood, Florida

Conditions: Osteoarthritis, Knee
Interventions: Naproxen Sodium (Aleve, BAY117031), Acetaminophen ER, Celecoxib, Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 5
States / cities: Chandler, Arizona • Pinellas Park, Florida • Chicago, Illinois + 2 more

Conditions: Caregiver Burden of People With Dementia
Interventions: Skill-building classes, Wait list control group; Other
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years to 100 Years
Enrollment: 225 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Corneal Edema After Cataract Surgery
Interventions: Ripasudil, Placebo; Drug
Lead sponsor: Kowa Research Institute, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 44
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Hemet, California + 37 more

Conditions: Obesity
Interventions: CagriSema (cagrilintide B and semaglutide I), CagriSema A; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Type 1 Diabetes
Interventions: AIDANET; Device
Lead sponsor: Marc Breton; Other
Eligibility: 18 Years to 60 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Glioblastoma
Interventions: Durvalumab, Standard radiotherapy, Bevacizumab; Drug · Radiation · Biological
Lead sponsor: Ludwig Institute for Cancer Research; Other
Eligibility: 18 Years and older
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 7
States / cities: Los Angeles, California • San Francisco, California • Baltimore, Maryland + 3 more

Conditions: Food Effects on Pharmacokinetics
Interventions: Milademetan Treatment A, Milademetan Treatment B, Milademetan Treatment C; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Breast Neoplasms
Interventions: Tamoxifen, Exemestane; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 30 Years and older · Female only
Enrollment: 4,740 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2013
U.S. locations: 57
States / cities: Birmingham, Alabama • Green Valley, Arizona • Green Velley, Arizona + 36 more

Search by objective public record fields.

Study to Evaluate the Safety and Efficacy of KITE-585 in Participants With Relapsed/Refractory Multiple Myeloma

Evaluation of the Potential Impact of a High-fat Meal on the Pharmacokinetics of CRS3123 in Healthy Adult Participants

Enhancing a Sustainable Pharmacy-based Immunization Program in Two States

Effects of an Antioxidant-Enriched Multivitamin Supplement on Inflammation and Oxidative Stress in Cystic Fibrosis

Bioequivalence Study Comparing Two Tablet Formulations of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) in Healthy Adult Subjects

Long-Term Extension Study of Ofatumumab in Subjects With Pemphigus Vulgaris

A Study to Assess the Effect of Multiple-Dose Administration of JNJ-42847922 on Midazolam and Warfarin in Healthy Participants

Gotistobart Long Term Extension (LTE) Study

A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics (PK) of Oral TAK-994 in an Acute Sleep Phase Delay Paradigm in Healthy Male Participants

A Study to Evaluate the Food Effect on Drug Availability, Pharmacokinetic (PK) Properties, Safety and Tolerability of Two Different Dose Combination Therapy of Saxagliptin/Dapagliflozin/Metformin Extended-release (XR) Against Individual Component Co-administration.

Examining the Impact of Tampon Use on the Vaginal Microbiota

In-Home Technology for Caregivers of People With Dementia and Mild Cognitive Impairment: Rural Homes

A Study on the Effects of LY2409021 on the Electrical Impulses of the Heart

A Phase 2 Single-Masked, Randomized Study of Latanoprost PPDS in Ocular Hypertension or Open-Angle Glaucoma

Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib

A Study to Learn if the Study Medicine Called Itraconazole and if Food Changes How the Body Processes the Other Study Medicine Called PF 07258669 in Older Adults or Healthy Adults

A Pilot Study Assessing the Treatment Responsiveness of a Novel Osteoarthritis Stiffness Scale

Demonstrating the Efficacy of a Spanish-Language Program for Latino Dementia Caregivers

A Study to Investigate the Safety and Efficacy of Ripasudil (K-321) Eye Drops After Cataract Surgery

A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Single Doses of Different Versions of Injectable CagriSema in Adults With Overweight or Obesity

Safety and Feasibility Testing of a Smaller Network Version of AIDANET

Phase 2 Study of Durvalumab (MEDI4736) in Patients With Glioblastoma

Food Effects on Milademetan Pharmacokinetics in Healthy Participants

Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer